Patents by Inventor Matthew Bernett

Matthew Bernett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bispecific binding agents binding to CLDN18.2 and CD3
    Patent number: 12378313
    Abstract: The present invention provides binding agents comprising at least two binding domains, wherein a first binding domain has specificity for CLDN18.2 and a second binding domain has specificity for CD3, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
    Type: Grant
    Filed: July 5, 2023
    Date of Patent: August 5, 2025
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Alex Nisthal, Gregory Moore
  • ANTI-CD20 ANTIBODIES AND THERAPEUTIC USES THEREOF
    Publication number: 20250197519
    Abstract: Provided herein are novel anti-CD20 antibodies that exhibit several advantageous properties as compared to rituximab.
    Type: Application
    Filed: October 22, 2021
    Publication date: June 19, 2025
    Applicant: Xencor, Inc.
    Inventors: Matthew BERNETT, Gregory MOORE, John R. DESJARLAIS
  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CD38
    Publication number: 20250109214
    Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.
    Type: Application
    Filed: September 10, 2024
    Publication date: April 3, 2025
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal
  • ENGINEERED IL-2 Fc FUSION PROTEINS
    Publication number: 20250092108
    Abstract: The present invention provides IL-2-Fc fusion proteins comprising IL-2 variants.
    Type: Application
    Filed: April 5, 2024
    Publication date: March 20, 2025
    Inventors: Matthew Bernett, John Desjarlais, Rajat Varma, Rumana Rashid
  • IL-15/IL-15RA heterodimeric Fc fusion proteins and uses thereof
    Patent number: 12239688
    Abstract: The present invention is directed to novel IL-15/IL-15R? heterodimeric Fc fusion proteins and uses thereof. The IL-15/IL-15R? heterodimeric Fc fusion proteins can be administered to a patient to treat cancer. In some cases, the IL-15/IL-15R? heterodimeric Fc fusion protein is administered in combination with a checkpoint blockage antibody such as a PD-1 antibody.
    Type: Grant
    Filed: March 22, 2021
    Date of Patent: March 4, 2025
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
  • IL-12 heterodimeric Fc-fusion proteins
    Patent number: 12234270
    Abstract: The present invention provides novel IL-12 Fc fusion proteins, methods of making and using the same. The IL-12 Fc fusion proteins are useful for treatment of cancer and can be used in combination with checkpoint blockade.
    Type: Grant
    Filed: April 11, 2022
    Date of Patent: February 25, 2025
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, John R. Desjarlais, Rajat Varma, Ke Liu, Nargess Hassanzadeh-Kiabi, Rumana Rashid
  • IL-15/IL-15RA HETERODIMERIC FC FUSION PROTEINS AND USES THEREOF
    Publication number: 20250057919
    Abstract: The present invention is directed to novel IL-15/IL-15R? heterodimeric Fc fusion proteins and uses thereof. The IL-15/IL-15R? heterodimeric Fc fusion proteins can be administered to a patient to treat cancer. In some cases, the IL-15/IL-15R? heterodimeric Fc fusion protein is administered in combination with a checkpoint blockage antibody such as a PD-1 antibody.
    Type: Application
    Filed: November 6, 2024
    Publication date: February 20, 2025
    Inventors: Matthew Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
  • OPTIMIZED ANTIBODY VARIABLE REGIONS
    Publication number: 20250034247
    Abstract: The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.
    Type: Application
    Filed: September 13, 2024
    Publication date: January 30, 2025
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • Bispecific and monospecific antibodies using novel anti-PD-1 sequences
    Patent number: 12152076
    Abstract: The present invention is directed to bispecific, heterodimeric checkpoint antibodies.
    Type: Grant
    Filed: March 16, 2022
    Date of Patent: November 26, 2024
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon, Alex Nisthal, Umesh Muchhal
  • Heterodimeric antibodies that bind CD3 and CD38
    Patent number: 12129309
    Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.
    Type: Grant
    Filed: May 4, 2022
    Date of Patent: October 29, 2024
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal
  • PD-1 TARGETED IL-15/IL-15RALPHA FC FUSION PROTEINS WITH IMPROVED PROPERTIES
    Publication number: 20240294593
    Abstract: The present invention relates to fusion proteins comprising variant IL-15 proteins, fusion proteins comprising variant anti-PD-1 antigen binding domains, and fusion proteins comprising variant IL-15 proteins and variant anti-PD-1 antigen binding domains. The present invention also relates to nucleic acid molecules, expression vectors, host cells and methods for making such fusion proteins and the use of such fusion proteins in the treatment of cancer.
    Type: Application
    Filed: January 18, 2024
    Publication date: September 5, 2024
    Inventors: John Desjarlais, Matthew Bernett, Michael Hedvat, Rajat Varma, Suzanne Schubbert, Christine Bonzon, Rumana Rashid, Juan Diaz, Patrick Holder, Christine Huang
  • COMPLEMENT COMPONENT C5 ANTIBODIES
    Publication number: 20240279317
    Abstract: The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure is related to C5 antibodies.
    Type: Application
    Filed: January 17, 2024
    Publication date: August 22, 2024
    Inventors: Peter C. Baciu, Yanbin LIANG, Jason Guu, Matthew Bernett, Umesh Muchhal, John Desjarlais
  • HETERODIMERIC ANTIBODIES THAT BIND MSLN AND CD3
    Publication number: 20240279356
    Abstract: The present invention is directed to antibodies, including novel antigen binding domains and heterodimeric antibodies, that bind Mesothelin (MSLN).
    Type: Application
    Filed: May 1, 2024
    Publication date: August 22, 2024
    Inventors: John R. Desjarlais, Matthew Bernett, Michael Hedvat, Veronica Gusti Zeng, Matthew S. Faber
  • Untargeted and targeted IL-10 Fc-fusion proteins
    Patent number: 12006345
    Abstract: The present invention provides untargeted and targeted IL-10-Fc fusion proteins, compositions and methods of use thereof. The targeted IL-10-Fc fusion proteins includes those that bind PD-1, TIGIT, CD8 and NKG2D.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: June 11, 2024
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Rajat Varma, Yoon Kyung Kim, Rumana Rashid, Alex Nisthal, Juan Diaz, Matthew Bernett, Michael Hedvat
  • Engineered IL-2 Fc fusion proteins
    Patent number: 11981717
    Abstract: The present invention provides IL-2-Fc fusion proteins comprising IL-2 variants.
    Type: Grant
    Filed: January 18, 2022
    Date of Patent: May 14, 2024
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, John Desjarlais, Rajat Varma, Rumana Rashid
  • HETERODIMERIC PROTEINS
    Publication number: 20240092871
    Abstract: In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc domain and a second antigen binding domain. In an additional aspect the heterodimeric antibody comprises a first monomer comprising a heavy chain comprising a first Fc domain and a single chain Fv region (scFv) that binds a first antigen, wherein the scFv comprises a charged scFv linker. The heterodimeric antibody further comprises a second monomer comprising a first heavy chain comprising a second Fc domain and a first variable heavy chain and a first light chain.
    Type: Application
    Filed: September 7, 2023
    Publication date: March 21, 2024
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • PD-1 targeted IL-15/IL-15R? Fc fusion proteins with improved properties
    Patent number: 11932675
    Abstract: The present invention relates to fusion proteins comprising variant IL-15 proteins, fusion proteins comprising variant anti-PD-1 antigen binding domains, and fusion proteins comprising variant IL-15 proteins and variant anti-PD-1 antigen binding domains. The present invention also relates to nucleic acid molecules, expression vectors, host cells and methods for making such fusion proteins and the use of such fusion proteins in the treatment of cancer.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: March 19, 2024
    Assignees: GENENTECH, INC., XENCOR, INC.
    Inventors: John Desjarlais, Matthew Bernett, Michael Hedvat, Rajat Varma, Suzanne Schubbert, Christine Bonzon, Rumana Rashid, Juan Diaz, Patrick Holder, Christine Huang
  • BISPECIFIC BINDING AGENTS BINDING TO CLDN18.2 AND CD3
    Publication number: 20240018234
    Abstract: The present invention provides binding agents comprising at least two binding domains, wherein a first binding domain has specificity for CLDN18.2 and a second binding domain has specificity for CD3, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
    Type: Application
    Filed: July 5, 2023
    Publication date: January 18, 2024
    Inventors: Matthew BERNETT, Alex NISTHAL, Gregory MOORE
  • Targeted IL-12 heterodimeric Fc-fusion proteins
    Patent number: 11851466
    Abstract: The present invention relates to targeted IL-12 heterodimeric Fc fusion proteins, where the fusion proteins bind to human PD-1 or human PD-L1.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: December 26, 2023
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, John R. Desjarlais, Rajat Varma, Ke Liu, Rumana Rashid, Nargess Hassanzadeh-Kiabi, Michael Hedvat
  • OPTIMIZED ANTIBODY VARIABLE REGIONS
    Publication number: 20230399401
    Abstract: The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.
    Type: Application
    Filed: June 9, 2023
    Publication date: December 14, 2023
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais